AN2 Therapeutics
an therapeutics is a clinical stage pivotal phase ready antibiotic product candidate for non tuberculous lung disease company developing treatments for rare chronic and serious infectious diseases with high unmet needs large market opportunity given the high unmet need the only approved therapy for lung disease had net sales of in its third year on the market ideal target product profile novel mechanism of action broad spectrum activity convenient once daily oral dosing superior profile compared to soc combination regimen in preclinical models multiple phase studies out to days of dosing support well tolerated dose and high probability of target attainment phase pivotal trial expected to support regulatory approval for treatment refractory mac lung disease plan to enroll first patient topline phase data mid alignment with on phase trial design and accepted fast track and orphan drug designations granted potential to develop to address additional geographies and indications we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
26 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
an therapeutics is a clinical stage company developing treatments for rare chronic and serious infectious diseases with high unmet needs we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
Investor Presentation
August 2022
an therapeutics is a clinical stage company developing treatments for rare chronic and serious infectious diseases with high unmet needs we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
IPO
March 2022
an therapeutics is a clinical stage pivotal phase ready antibiotic product candidate for non tuberculous lung disease company developing treatments for rare chronic and serious infectious diseases with high unmet needs large market opportunity given the high unmet need the only approved therapy for lung disease had net sales of in its third year on the market ideal target product profile novel mechanism of action broad spectrum activity convenient once daily oral dosing superior profile compared to soc combination regimen in preclinical models multiple phase studies out to days of dosing support well tolerated dose and high probability of target attainment phase pivotal trial expected to support regulatory approval for treatment refractory mac lung disease plan to enroll first patient topline phase data mid alignment with on phase trial design and accepted fast track and orphan drug designations granted potential to develop to address additional geographies and indications we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
Related slides by other companies
ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
AstraZeneca
Investor Day
September 2022
rare disease | AstraZeneca
Genelux
Investor Presentation
October 2023
diversified designs and indications exploit competitive advantages bene | Genelux
Genelux
Investor Presentation
December 2023
program builds on completed trials to exploit competitive advantages estimated billion dollar plus annual commercial opportunity us | Genelux
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io